Glenmark Pharmaceuticals shares jump 3.5% as U.S. FDA approves Fluticasone Propionate Nasal Spray
Why did Glenmark Pharmaceuticals Ltd shares jump today?
Glenmark Pharmaceuticals Ltd shares experienced a significant upward movement today, rising by 3.5% to reach a current price of ₹2386.6, as observed at 04:47 PM on Monday. This surge in the stock price is directly linked to a positive regulatory development for the company.
The primary catalyst for this rally was the announcement that Glenmark Pharmaceuticals has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray. This product is an authorised generic version of the widely used allergy medication, Flonase. The company confirmed in its filing that the nasal spray is bioequivalent and therapeutically equivalent to the reference brand, making it a direct competitor in the U.S. market.
This approval represents a significant milestone, as it allows Glenmark to launch and distribute this product through its U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA. The entry into the lucrative U.S. generics market for a well-known drug like Flonase is expected to contribute to future revenue growth, which investors have viewed very positively, leading to the strong share price performance seen today.
What does Glenmark Pharmaceuticals Ltd do?
Glenmark Pharmaceuticals Limited is a pharmaceutical company that develops and markets products for the U.S. market. The company received approval from the U.S. FDA for a new product and will distribute it through its U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA.
The approved product is Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase® Nasal Spray, 0.05 mg/spray.
Glenmark Pharmaceuticals Ltd Financials
In CroresGlenmark Pharmaceuticals Ltd reported an increase in both revenue and net profit for the first quarter of fiscal year 2027, ending June 2026, compared to the previous quarter ended March 2026. Revenue grew from ₹3760.28 crores to ₹3931.73 crores, marking a sequential increase of approximately 4.55%. More significantly, net profit saw a substantial rise of about 60.2% sequentially, jumping from ₹301.41 crores in March 2026 to ₹482.92 crores in June 2026, indicating a strong and positive financial trend for the period.
Glenmark Pharmaceuticals Ltd Shareholding Pattern
Promoter holding stands at 46.65% of the total share capital. Foreign Institutional Investors (FIIs) hold 20.89% stake in the company, while Domestic Institutional Investors (DIIs) hold 18.6%. Public shareholders hold the remaining 13.85% stake in Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd FAQs
Q: Why did Glenmark shares jump 3.5% today?
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
As per the latest data, promoters hold 46.65% stake in Glenmark Pharmaceuticals Ltd, while FII holding stands at 20.89%. Domestic institutional investors hold 18.6%, and public shareholders account for 13.85% of the equity.
Q: What is the current stock price of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd shares are currently trading at ₹2386.6, recording a gain of 3.5% from the previous close.
Q: What is the market capitalization of Glenmark Pharmaceuticals Ltd?
The company currently has a market capitalization of ₹67355.74 crore, reflecting its valuation in the Indian equity market.